Clinical trials: Experimental Group
Xerosis, Dry Skin
Dermatological Acceptability and Efficacy in Improving Xerosis, Skin Hydration, and Barrier Function
The goal of this clinical trial is to evaluate the dermatological safety and efficacy of a moisturizing product in participants with moderate to severe xerosis of the lower limbs.
- Trial name
- NCT07820943
- Testing
- moisturizing cream
- Where
- Brazil
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Brainfarma Industria Química e Farmacêutica S/A
Respiratory Disorders
A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.
The purpose of this study is to test if the vaccine is working well in COPD patients aged 40 to 80 years old to reduce episodes of worsening symptoms ("exacerbations") and to gather further information on safety and immune…
- Trial name
- NCT03281876
- Testing
- NTHi Mcat investigational vaccine (GSK3277511A)
- Where
- 67 sites in United States, Belgium and 6 more
- Volunteers
- 606 people
- Sponsor
- GlaxoSmithKline
Pneumonia, Pneumococcal
Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.
- Trial name
- NCT04278248
- Testing
- 23-Valent Pneumococcal Polysaccharide Vaccine
- Where
- China
- Volunteers
- 1,940 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Healthy Volunteers
A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers
This is a randomized open comparative parallel group study of the safety and pharmacokinetics of GNR-068 and Stelara® in healthy volunteers. Participants received a single subcutaneous dose of ustekinumab 45 mg.
- Trial name
- NCT06481215
- Testing
- GNR-068, Stelara®
- Where
- 2 sites in Russia
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- AO GENERIUM
Acute Bronchitis
To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis
A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients with Acute Bronchitis
- Trial name
- NCT07061925
- Testing
- ALC-2203-1, ALC-2203-2, ALC-2203-AC
- Where
- South Korea
- Volunteers
- 169 people
- Sponsor
- Korea Arlico Pharm. Co., Ltd
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
- Trial name
- NCT01059617
- Testing
- GSK Biologicals' FluLaval®, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination to Evaluate Efficacy, Safety and Immunogenicity
- Trial name
- NCT05911061
- Testing
- High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), control group
- Volunteers
- 4,950 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Schizophrenia
Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers
This study will consist of 2 parts: Part Ⅰ - Single Ascending Dose (SAD) study, Part Ⅱ - Food Effect (FE) study
- Trial name
- NCT06105151
- Testing
- VV119(SAD), VV119(FE)
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Knee Osteoarthritis
Study on Efficacy and Safety of Chondroitin Sulfate + Glucosamine Hydrochloride Versus Celecoxib in Knee Osteoarthritis
The purpose of this study is to determine whether the combination of Chondroitin sulfate (CS) and Glucosamine Hydrochloride (GH) has similar efficacy to Celecoxib (CE) in the treatment of patients with moderate to severe knee…
- Trial name
- MOVES (NCT01425853)
- Testing
- Chondroitin/Glucosamine (Droglican), Celecoxib
- Where
- Spain
- Volunteers
- 606 people
- Sponsor
- Bioiberica
Peripheral Artery Disease
A Trail of Drug-coated Balloon Treating Below The Knee Arterial Diseases
This is a prospective, multicenter, randomized controlled trail using drug-coated balloon to treat below the knee arterial stenosis or occlusion.
- Trial name
- NCT05415995
- Testing
- Drug eluting Balloon
- Where
- 20 sites in China
- Volunteers
- 202 people
- Sponsor
- Zhejiang Zylox Medical Device Co., Ltd.
Noninvasive Ventilation, Respiratory Insufficiency
A Feasibility Study Evaluating the Use of a Non-invasive Ventilation Mask
Evaluate the clinicians assessment of the use of an oro-nasal mask during non-invasive ventilation (non-intubated) with a feasibility study.
- Trial name
- mask (NCT02383719)
- Testing
- Oro-nasal Mask
- Volunteers
- 18 people
- Sponsor
- Convergent Engineering, Inc.
Healthy Term Infants
Growth and Tolerance of Healthy Term Infants to a New Infant Formula
The objective of this study is to evaluate the effect of two experimental milk-based infant formulas on the growth and gastrointestinal (GI) tolerance of term infants.
- Trial name
- NCT01137877
- Testing
- Milk based infant formula powder, Investigational Infant Formula #1, Investigational Infant Formula #2
- Where
- 20 sites in United States
- Volunteers
- 399 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Benign Prostatic Hyperplasia
Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath
To demonstrate the safety and efficacy of the Urocross Expander System/Retrieval Sheath and the procedure to treat patients with symptomatic Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT05400980
- Testing
- Urocross implant
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- Prodeon Medical, Inc
Epidemic Meningitis, Meningococcal Vaccines
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months
The goal of this clinical trial is to evaluate the immunogenicity, safety, and persistence of the immune response of a group ACYW135 meningococcal conjugate vaccine in healthy children aged 6 to 11 months.
- Trial name
- NCT07505823
- Testing
- experimental vaccine, Active Comparator vaccine
- Where
- 2 sites in China
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza, Human
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately 7700 male and female adults aged 50 years and older (approximately equally…
- Trial name
- NCT06015282
- Testing
- Investigational aQIVc, licensed QIVr, licensed aQIV
- Where
- 96 sites in United States, Canada and 6 more
- Volunteers
- 7,741 people, healthy volunteers welcome
- Sponsor
- Seqirus
Colitis, Ulcerative
Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis
The purpose of the study was to assess preliminary efficacy, safety, and tolerability of LYS006 in adult patients with mild to moderate ulcerative colitis and to determine if LYS006 has an adequate clinical profile for further…
- Trial name
- NCT04074590
- Testing
- LYS006
- Where
- 9 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 23 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease
Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease
The aim of this study is to evaluate the safety, feasibility, tolerability and efficacy of a new buccal film of montelukast in patients with mild to moderate Alzheimer's disease.
- Trial name
- BUENA (NCT03402503)
- Testing
- Montelukast buccal film
- Where
- 12 sites in Canada
- Volunteers
- 52 people
- Sponsor
- IntelGenx Corp.
Health Behavior, Nutrition, Healthy
Effects of Pro2col Application on Health Outcomes
The purpose of this study is to test the effectiveness of a novel smartphone application (Pro2col Health) in regard to multiple health outcomes and health behaviors in healthy middle-aged adults.
- Conditions
- Health Behavior, Nutrition, Healthy, Activity, Motor
- Trial name
- NCT06738641
- Testing
- Pro2col Health, Control
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Applied Science & Performance Institute
Embolism and Thrombosis, Embolism
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings
The purpose of this quasi-experiment study, which could also be classified as a prospective observational intervention study, is to assess the impact of cytochrome P450 2C9 (CYP 2C9) and vitamin K epoxide reductase complex…
- Conditions
- Embolism and Thrombosis, Embolism, Vascular Diseases, Warfarin
- Trial name
- MHSMayoWarf1 (NCT00830570)
- Testing
- CYP 2C9 and VKORC1 Testing for Warfarin
- Where
- United States
- Volunteers
- 1,635 people
- Sponsor
- Medco Health Solutions, Inc.
Seizures, Epilepsy
Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery
This study will asses the safety and efficacy of BGG492 in reducing the seizure rate in therapy-refractory partial seizures.
- Trial name
- NCT00887861
- Testing
- Investigational new drug, company code: BGG492
- Where
- 6 sites in Germany
- Volunteers
- 37 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.